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ABSTRACT
Objective: The objective of this study is to find the effect of seed extract of Trigonella foenum graecum on the inhibition of α-glucosidase and dipeptidyl 
peptidase-4 (DPP-4) enzyme activity by in vitro method.
Methods: Methanolic seed extract of T. foenum graecum seed was prepared and supplied by Sami Labs, Bengaluru, on request. For alpha-glucosidase 
inhibition assay, the following concentrations (0, 20, 40, 60, 80, and 100 µg/ml) of extracts and for DPP-4 inhibition assay (0, 5, 10, 20, 40, 80, 
160, and 320d µg/ml) concentrations were used. The absorbance was measured at 540 and 405 nm using multiplate reader, and the percentage of 
α-glucosidase and DPP-4 enzyme inhibitory activity of extract fractions was calculated. Acarbose for alpha-glucosidase inhibition and vildagliptin for 
DDP-4 inhibition were used as standard drugs. The IC50 value for alpha-glucosidase inhibition and DPP-4 inhibition was determined.
Results: The maximum alpha-glucosidase inhibitory activity of T. foenum graecum extract at 100 μg/ml was 68% (p<0.05) with IC50 value of 57.25 
when compared to the acarbose (STD) of 94% with IC50 values of 42.78. The maximum percentage of DPP-4 inhibition of T. foenum graecum extract 
at 320 μg/ml is 77.84% (p<0.01) with IC50 value of 52.26 when compared to the vildagliptin (STD) it is 80.15% with IC50 value of 22.98.
Conclusion: The results of the in vitro studies show that T. foenum graecum seed extract has significant alpha-glucosidase and DPP-4 inhibition. 
Further in vivo and clinical studies are necessary to establish the antihyperglycemic and antidiabetic potential of T. foenum graecum seed extract for 
the treatment of Type 2 diabetes mellitus.
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INTRODUCTION
Diabetes mellitus is a metabolic syndrome, characterized by hyperglycemia 
and abnormality of carbohydrate, protein, and fat metabolism due to 
relative or absolute insulin deficiency leading to micro- and macrovascular 
complications [1].  As per the International Diabetes Federation, 366 
million people are suffering from diabetes, and which may increase two 
fold by 2030. In India alone, 40 million people are suffering from diabetes. 
India is going to lead the world with 60 million diabetic patients by 
2025 [2]. In Type 2 diabetes mellitus, the postprandial hyperglycemia plays 
an important role in the progression and complications of the disease. Even 
though dietary management plays a vital role in the management of Type 
2 diabetes, antidiabetic agents such as α-glucosidase inhibitors play a vital 
role in controlling postprandial hyperglycemia [3].
In India, our diet constitutes >75% of carbohydrates, and hence, 
changing the entire dietary pattern is practically not feasible. Measures 
which can restrict the carbohydrate absorption from gut by palatable 
natural products are an important area for research. Recent studies 
showed that natural drugs are nontoxic, safe, and less of side effects, 
and therefore, herbal medicines are likely to be used as primary health-
care treatment in diabetes mellitus [4]. Hence, this study is designed to 
evaluate the inhibitory role of edible herbal plant Trigonella foenicum 
graecum on α-glucosidase and dipeptidyl peptidase-4 (DPP-4) enzyme 
activity. These important actions will help in reducing the carbohydrate 
absorption and enhancing the incretins such as GLP 1 and GIP in the 
control of hyperglycemia in Type 2 diabetes.
Trigonella foenum-graecum (fenugreek)
T. foenum-graecum (also known as fenugreek, locally called as methi) 
is widely used as spice and household medicine in India. It possesses 
many biological as well as pharmacological actions in reducing various 
ailments. Experimental studies showed that it has got hypolipidemic, 
anti-inflammatory, and reducing gastrointestinal diseases [5], anti-
inflammatory activity as local application in the form of gel [6]. Earlier 
animal studies suggested hypoglycemic and antihyperglycemic action 
of oral fenugreek seed powder in diabetic rat models [7]. Most of 
the studies showed antidiabetic activity and prevention of diabetic 
complications, but exact mechanism of action is not explored. Hence, 
this study is conducted to explore the important mechanism of gut 
absorption of glucose, i.e., alpha-glucosidase inhibition and incretin-
based action, i.e., DPP-4 inhibitory action of T. foenum graecum.
METHODS
Fenugreek (T. foenum-graecum) seed extract (Fenusterols) was prepared 
and supplied by Sami Labs Ltd., Bengaluru, on request. Product Code 
0566, BatchNo. H170111. Methanolic seed extract was prepared and 
supplied. The contents are steroidal saponins by gravimetry 52.04% 
w/w, alkaloids 0.630 and disogenin by HPLC 1.51% w/w. Physical, 
chemical, and microbiological testing done and certificate of analysis 
was issued by the Sami Labs Ltd. (www.samilabs.com). This extract was 
used for the two in vitro tests.
Determination of alpha-glucosidase inhibitory activity
Materials required
Phosphate buffer: 50 mM, pH 6.8.
Sodium carbonate: 0.1M.
p-Nitrophenyl-α-D-glucopyranoside (PNPG): 1 mM.
Sample: Extract with a range of concentrations 0–100 μg/ml.
Alpha-glucosidase: 1 µ/ml-SRL.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i10.28766
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Procedure
Alpha-glucosidase inhibitory activity of T. foenum-graecum extracts 
was carried out according to the method of Bachhawat et al. with slight 
modification [8]. Reaction mixture containing 50 μl phosphate buffer, 
10 μl alpha-glucosidase, and 20 μl of varying concentrations of extracts 
was pre-incubated at 37°C for 15 min. Then, 20 μl PNPG was added as 
a substrate and incubated further at 37°C for 30 min. The reaction was 
stopped by adding 50 μl sodium carbonate. The yellow color produced 
was read at 405 nm. Each experiment was performed along with 
appropriate blanks. Acarbose at various concentrations (0–100 μg/ml) 
was included as a standard. Negative control without extracts was set 
up in parallel. The result is expressed as percentage inhibition.
Calculation
Inhibition (%) = Abs. control - Abs. sample/Abs. control ×100.
DPP4 inhibitory in vitro assay
DPP4, also known as CD26 and adenosine deaminase complexing 
protein 2, is a serine exopeptidase that cleaves X-Proline and X-Alanine 
residues from the N-termini of polypeptides. DPP4 is a transmembrane 
glycoprotein whose activity regulates the bioactivity of multiple peptides 
such as growth factors, chemokines, and neuropeptides. DPP4 plays a 
major role in glucose metabolism through the regulation of glucagon-like 
peptide-1, and inhibitors of DPP4 are commonly used for the treatment 
of Type 2 diabetes [9]. DPP4 also plays an important role in immune 
regulation and may play a role in tumor suppression. In this assay, 
DPP4 cleaves a non-fluorescent substrate, H-Gly-Pro-7-amino-4-methyl 
coumarin (AMC), to release a fluorescent product, AMC (lex = 360/lem = 
460 nm). One unit of DPP4 is the amount of enzyme that will hydrolyze 
the DPP4substrate to yield 1.0 m mole of AMC per minute at 37°C [10].
Methods and materials
• DPP4 Assay Buffer 25 ml (Catalog Number MAK088A)
• DPP4 Substrate, H-Gly-Pro-AMC 0.2 ml (Catalog Number MAK088B)
• DPP4 Positive Control 20 ml (Catalog Number MAK088C)
• AMC Standard, 1 mM 0.1 ml Catalog Number MAK088D
• DPP4 Inhibitor, Vildagliptin 1 ml.
Procedure
All samples and standards should be run in duplicate. AMC standards 
for fluorometric detection. Dilute 10 ml of the 1 mM AMC standard 
solution with 990 ml of water to prepare a 10 mM (10 p mole/ml) 
standard solution. Add 0, 2, 4, 6, 8, and 10 ml of the10 mM standard 
solution into a 96-well plate, generating 0 (blank), 20, 40, 60, 80, and 
100 p mole/well standards. Add DPP4 Assay Buffer to each well to 
bring the volume to 100 ml.
Sample preparation
Samples can be directly added to the wells. A sample blank is required 
for each test sample. Prepare a duplicate well for each sample to be 
used as the sample blank. Bring test samples and sample blanks to a 
final volume of 50 ml with DPP4 assay buffer. For the positive control, 
add 1–2 ml of the DPP4 positive control solution to wells and adjust to 
50 ml with the DPP4 assay buffer.
Assay reaction
1. Add 10 ml of the DPP4 assay buffer to each of the sample wells. Add 
10 ml of the DPP4 inhibitor to each of the sample blank wells. Mix 
well by pipetting, and incubate for 10 min at 37°C.
2. Set up the Master Reaction Mix according to the scheme in Table 1. 40 ml 
of the Master Reaction Mix is required for each sample and sample blank 
well. Do not add the Master Reaction Mix to the standard curve wells.
Reagent volume
1. Add 40 ml of the Master Reaction Mix to each of the wells. Mix well by 
pipetting. Cover the plate and protect from light during the incubation.
2. Incubate the plate at 37°C. After 5 min, take the initial measurement 
(T initial). Measure the fluorescence intensity (FLU) initial, lex = 360/
lem = 460 nm).
3. Note: It is essential (FLU), initial is in the linear range of the standard 
curve.
4. Continue to incubate the plate at 37°C taking measurements (FLU) 
every 5 min. Protect the plate from light during the incubation.
5. Continue taking measurements until the value of the most active 
sample is greater than the value of the highest standard (100 p mole/
well). At this time, the most active sample is near or exceeds the end 
of the linear range of the standard curve.
6. The final measurement (FLU final) for calculating the enzyme activity 
would be penultimate reading or the value before the most active 
sample is near or exceeds the end of the linear range of the standard 
curve, as shown in step 5. The time of the penultimate reading is T 
final.
Calculations
Corrected for the background by subtracting the final measurement 
([FLU] final) obtained for the 0 (blank) AMC standard from the final 
measurement ([FLU] final) of these standard and samples. Background 
values can be significant and must be subtracted from all readings. Plot 
the standard curve.
Note: A new standard curve must be set up each time the assay is run.
Calculate the change in measurement from T initial to T final for the 
samples.
DFLU = (FLU) final – (FLU) initial
Furthermore, subtract the sample blank D measurement value from the 
sample D measurement values. Compare the DFLU of each sample to 
the standard curve to determine the amount of AMC released by the 
DPP4 assay between T initial and T final (B).
The DPP4 activity of a sample may be determined by the following 
equation:
DPP4 Activity = B × Sample dilution factor/(Reaction time) × V
B = Amount (p mole) of AMC released between T initial and T final
Reaction time = T final - T initial (min)
V = Sample volume (ml) added to well
DPP4 activity is reported as p mole/min/ml = micro unit/ml
One unit of DPP4 is the amount of enzyme that will hydrolyze the DPP4 
substrate to yield 1.0 m mole of AMC per minute at 37°C.
Statistical analysis
The collected data from the observations were analysed by descriptive 
statistics such as mean, standard deviation, standard error and % of 
inhibition [11]. The statistical analysis was performed using Microsoft 
Excel program 2013.
RESULTS AND DISCUSSION
Alpha-glucosidase enzyme inhibitory action
This in vitro study shows that maximum alpha-glucosidase inhibition 
of T. foenum-graecum at 100 µg/ml is 68% (p<0.05 ) with IC50 value of 
57.25 when compared to the acarbose (STD) of 94% with IC50 values of 
42.78 (Table 2 and Fig. 1).
This activity confirms the action of T. foenum-graecum on in vitro 
alpha-glucosidase inhibitory potential by the similar study [12]. 
Another similar study which evaluated the antidiabetic potential of 
Table 1: Master reaction mix
DPP4 Assay Buffer 38 ml DPP4 substrate 2 ml
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phytoconstituents such as alkaloids, peptidoglycans, saponins, guar 
gum, pectins, glycosides and their mode of action on metabolic pathway. 
It also confirmed that T. foenum-graecum has antihyperglycemic action 
by interfering with carbohydrate absorption and digestion [14]. 
T. foenum-gracum an important dietary ingredient which may be 
developed into an important antidiabetic medication to control the post 
prandial blood glocose.
DPP-4 ENZYME INHIBITORY ACTION
The maximum percentage of DPP-4 inhibition of T. foenum graecum 
extract at 320 μg/ml is 77.84% (p<0.01 ) with IC50 value of 52.26 when 
compared to the vildagliptin (STD) is 80.15% with IC 50 value of 22.98. 
(Refer Table 3 and Fig. 2).
A similar research study evaluated the Indonesian herbs for in vitro DPP4 
inhibition [15]. In that study, Klabet (Indonesia) (T. foenum-graecum) 
showed 72.29% DPP-4 inhibition, whereas our study showed 77.84% DPP-
4 inhibition at highest concentration. This confirms that T. foenum graecum 
possesses a significant DPP-4 inhibition potential and it could be a promising 
drug target for edible herbal-based DPP-4 inhibitor. A meta-analysis of 
clinical trials done on the effect of fenugreek (T. foenum graecum) intake 
on glycemia [16] clearly concluded that fenugreek seeds have beneficial 
effects on glycemic control in diabetic patients. Enhancement of antidiabetic 
activity by T. foenum-graecum (4-hydroxyisoleucine) was demonstrated 
by a animal study [17] which again confirms the antidiabetic potential of 
the study extract. However, more clinical studies with well-characterized 
fenugreek preparations are needed for human use. Many such articles even 
stressed the importance of T. foenum graecum to be included in the drug 
therapy for the prevention and management of diabetes.
CONCLUSION
The in vitro studies showed that seed extract of T. foenum graecum 
has significant alpha-glucosidase and DPP-4 inhibition activity. 
Further in vivo and clinical studies are necessary to establish the 
antihyperglycemic and antidiabetic potential of T. foenum graecum for 
the treatment of Type 2 diabetes mellitus.
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Table 2: Percentage inhibitory activity of Fenugreek (Trigonella Foenum-graecum) seed extract on alpha-glucosidase enzyme activity in 
comparison with Acarbose (n=6)
Concentrations of sample (μg/ml) Mean±SD (n=6) % Inhibition of fenugreek Mean±SD (n=6) % Inhibition of Acarbose
0 0.713±0.0024 0.22 0.73±0.0024 0.22
20 0.734±0.007 25 0.510±0.006 45
40 0.621±0.011 34 0.410±0.002 57
60 0.510±0.006 45 0.301±0.001 68
80 0.412±0.002 56* 0.135±0.009 84
100 0.301±0.001 68* 0.124±0.020 94
Values are mean±SD; (n=6) *p<0.05 when compared to Acarbose
Table 3: Percentage inhibitory activity of (Trigonella foenum-graecum) on dipeptidyl peptidase-IV enzyme in comparison with 
vildagliptin (n=8)
Concentrations of sample (μg/ml) Mean±SD (n=8) % Inhibition of fenugreek Mean±SD (n=8) % Inhibition of vildagliptin
0 0.715±0.005 0.66 0.952±0.0058 0.66
5 0.687±0.006 4.52 0.826±0.0052 13.66
10 0.680±0.004 4.41 0.710±0.0030 25.32
20 0.594±0.006 17.44 0.602±0.0119 36.13
40 537±0.007 25.21 0.480±0.0072 48.63
80 0.309±0.006 56.83 0.326±0.0096 66.18
160 0.293±0.010 59.85 0.260±0.0070 73.32
320 0.223±0.011 77.84* 0.179±0.0087 80.15
Values are mean±SD; (n=8) *p<0.01 when compared to vildagliptin
Fig. 1: Percentage inhibitory activity of Fenugreek (Trigonella 
foenum-graecum) seed extract on alpha-glucosidase enzyme in 
comparison with acarbose
Fig. 2: Percentage inhibitory activity of Trigonella foenum-
graecum on dipeptidyl peptidase-IV enzyme in comparison with 
Vildagliptin
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